While the study identifies key metabolic shifts in retinoic and arachidonic acid pathways, were any targeted metabolomic validations performed to confirm these findings? Given the broad scope of untargeted metabolomics, verifying specific metabolite changes could strengthen the conclusions. Additionally, the behavioral assays suggest neurobehavioral alterations, but how do the authors differentiate between direct metabolic effects versus compensatory neural adaptations? Were any additional neurophysiological assessments, such as electrophysiology or imaging, considered to distinguish primary metabolic disruptions from secondary behavioral responses?
